[HTML][HTML] FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann, JG Cyster, T Hla - American Journal of Transplantation, 2004 - Elsevier
The novel immunomodulator FTY720 is effective in experimental models of transplantation
and autoimmunity, and is currently undergoing Phase III clinical trials for prevention of
kidney graft rejection. In contrast to conventional immunosuppressants, FTY720 does not
impair T-and B-cell activation, proliferation and effector function, but interferes with cell traffic
between lymphoid organs and blood. The molecular basis for the mode of action of the drug
has only recently been established. FTY720, after phosphorylation, acts as a high-affinity …
and autoimmunity, and is currently undergoing Phase III clinical trials for prevention of
kidney graft rejection. In contrast to conventional immunosuppressants, FTY720 does not
impair T-and B-cell activation, proliferation and effector function, but interferes with cell traffic
between lymphoid organs and blood. The molecular basis for the mode of action of the drug
has only recently been established. FTY720, after phosphorylation, acts as a high-affinity …